Tumor vaccine treatment method

Abstract

The invention discloses a tumor vaccine treatment method, which comprises the following steps: patient preparation, preoperative examination, informed agreement, tumor tissue resection, postoperativetreatment, gp96 protein purification and clinical treatment. According to an immunization procedure, the patient is subjected to administered subcutaneous or intradermal injection with a tumor autologous gp96 vaccine, and gp96 interacts with heat shock protein receptors (CD91, CD36, SR-A, Lox-1, TLR2 and TLR4) on the surface of antigen presenting cells, the maturation and activation of antigen-presenting cells can be promoted, which are realized by up-regulating of cell surface molecules and secreting of cytokines and chemokines, the adjuvant properties of gp96 and its bonded tumor-derived polypeptides provide an ideal environment for cross-presenting MIHC I and MHC II restricted polypeptides, tumor autologous gp96 activates tumor cells and micrometastases of tumor cell-specific CD4<+> helper T cells and cytotoxic CD8<+> T cells, the method has good immunization characteristic, and the treatment effect is better than that of the operation and chemotherapy.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a tumor vaccine treatment method. Background technique [0002] The so-called tumor vaccine therapy is actually an important means of biological therapy, which can actively identify and effectively kill malignant tumor cells by activating the body's own immunity, and has a high degree of specificity. Tumor vaccines can also induce immune memory cells, produce long-lasting immune effects, and prevent tumor metastasis and recurrence. Therefore, tumor therapeutic vaccines are an ideal specific active immunotherapy. Tumor vaccines are based on tumor antigens, and through appropriate antigen delivery systems and vaccine adjuvants, activate the body's specific immune response, including humoral immunity and cellular immunity, especially CD8 + T cells (killer T cells, CTLs) generate anti-tumor immune response "The anti-tumor immune activity of tumor vaccines has not only been confirme...

AI Technical Summary

Problems solved by technology

Tumor vaccines are based on tumor antigens, and through appropriate antigen delivery systems and vaccine adjuvants, activate the body's specific immune response, including humoral immunity and cellular immunity, especially CD8 + T cells (killer T cells, CTLs) generate anti-tumor immune response "The anti-tumor immune activity of tumor vaccines has not only been confirmed in animal experiments, but also a variety of tumor vaccines have entered the stage of clinical trials. It is surgery or chemotherapy, which brings different degrees of side effects to patients, and the treatment effect is not very satisfactory.

Images